Renal Cell Carcinoma

Drs Tannir and Tykodi share their differing views on the effect an IO and a TKI agent have when combined for advanced clear cell RCC treatment.

During a Targeted Oncology case-based roundtable event, Timothy M. Kuzel, MD, discussed the treatment options for patients with clear cell renal cell carcinoma.

Bradley A. McGregor, MD, discusses new trials of intensified combination regimens for frontline treatment of patients with intermediate- or poor-risk advanced renal cell carcinoma.

Shared insight on optimal dosing strategies with first-line tyrosine kinase inhibitor and immunotherapy combinations for patients with advanced clear cell renal cell carcinoma.

Sumanta Pal, MD, an expert hematologist/oncologist, evaluates the combination of cabozantinib + nivolumab as first-line therapy for advanced clear cell renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Chung-Han Lee, MD, PhD, discussed the latest data supporting the use of lenvatinib/pembrolizumab as frontline therapy for patients with advanced clear cell renal cell carcinoma.

Adjuvant pembrolizumab continues to demonstrate these impressive results with disease-free survival in renal cell carcinoma, according to Thomas Powles, MD, MBBS, MRCP.

During a live virtual event, Robert J. Motzer, MD, discussed the role of risk assessment in treating a patient with clear cell renal cell carcinoma. This is the first of 2 articles based on this event.

An oncologist explains his dosing strategies for lenvatinib in advanced clear cell RCC, with reference to the design of the KEYNOTE-426 trial.

Dr Moshe Ornstein shares his take on the survival, efficacy, and toxicity data of the CLEAR trial in advanced clear cell RCC.

Helen H. Moon, MD, discusses the results of the TIVO-3 trial of tivozanib for patients with recurrent clear cell renal cell carcinoma.

Centering discussion around the combination of lenvatinib + pembrolizumab in advanced clear cell RCC, Hans Hammers, MD, considers the role of this combination regimen in the first-line treatment setting.

Expert hematologist/oncologist Brian Rini, MD, spearheads a comprehensive discussion on the broad treatment landscape for advanced clear cell renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Sumanta K. Pal, MD, discussed the choice of frontline therapy for a favorable-risk patient with advanced clear cell renal cell carcinoma.

With encouraging overall response and disease control rates, lenvatinib plus pembrolizumab has the potential to be a frontline treatment option for non–clear cell renal cell carcinoma.

The combination of belzutifan and cabozantinib was well tolerated in patients with treatment-naïve advanced clear cell renal cell carcinoma, according to findings presented at the 2022 ESMO Congress.

The combination of belzutifan and cabozantanib maintained antitumor activity in patients with advanced clear cell renal cell carcinoma who previously received immunotherapy.

Patients with more than 2 tertiary lymphoid structures, high Ki-67, and PD-1 positivity had high response rates to nivolumab plus ipilimumab.

A reduced the risk for disease progression by 27% was seen with the combination of cabozantinib added to nivolumab and ipilimumab in previously untreated advanced renal cell carcinoma.

Scott Tykodi, MD, PhD, reviews data from the CLEAR trial investigating 2 IO combination therapies for advanced renal cell carcinoma treatment.

Drs Tannir, Tykodi, and Ornstein debate whether single-agent TKI therapies still have a place in advanced clear cell RCC treatment, especially for favorable-risk patients.

A more tailored approach to treatment with PD-1 and CTLA-4 immune checkpoint blockade led to improved responses for patients with advanced renal cell carcinoma in both the first- and second-line settings, according to final results from the phase 2 TITAN-RCC trial.

Even after additional follow-up, the CLEAR trial showed a benefit for the combination of lenvatinib and pembrolizumab over sunitinib in patients with advanced clear cell renal cell carcinoma.

Adjuvant nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high risk for relapse after nephrectomy failed to significantly improve disease-free survival vs placebo in part A of the phase 3 CheckMate 914 trial.

Perioperative nivolumab in patients with RCC, at high risk for recurrence, did not see an improved RFS, but analyses within the phase 3 trial could inform future research.